echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Heart: The latest results of real-world analysis once again confirmed the clinical benefits and safety of non-vitamin K antagonist oral anticoagulants

    Heart: The latest results of real-world analysis once again confirmed the clinical benefits and safety of non-vitamin K antagonist oral anticoagulants

    • Last Update: 2021-03-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    For patients with atrial fibrillation (AF) who are at high risk of stroke, all major guidelines recommend oral anticoagulant therapy.


    Recently, Professor A John Camm, a clinical and academic group of cardiology at St.


    The GARFIELD-AF study is a prospective, multinational, observational study that included 25,551 adults who were recently diagnosed with non-valvular atrial fibrillation and had at least one risk factor for stroke.


    Among them, 8605 patients (median age 73 years old, 52% males) were treated with VKAs, 2090 patients (median age 72 years old, 55% males) were treated with DTI, and 7694 patients (median age 75 years old, 53% males) ) Using factor Xa inhibitors, 7162 patients (median age 73 years, 54% male) did not receive any oral anticoagulant therapy.


    The results showed that compared with patients who were not treated with oral anticoagulants, the use of any oral anticoagulant can reduce mortality (HR=0.


    However, compared with patients without oral anticoagulation therapy, NOACs treatment reduced mortality (HR=0.


    Compared with VKAs, NOACs treatment can reduce all-cause mortality (3.


    In the vast majority of patients with atrial fibrillation, international guidelines recommend that NOACs are widely superior to VKAs, because clinical trials have always shown the non-inferiority and better safety of NOACs, and reduce the risk of intracranial hemorrhage.


    Original source:

    A John Camm, Keith AA Fox, Saverio Virdone, et al.


    bmj.
    com/content/early/2021/02/15/heartjnl-2020-318420" target="_blank" rel="noopener">Comparative effectiveness of oral anticoagulants in everyday practice.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.